Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) has signed a non-binding letter of intent (LOI) to combine with global healthcare holding company OSR Holdings, Ltd.
Seoul, South Korea-based OSR leverages its international network of partners in the US, Europe, and South Korea to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the ultimate goal of addressing unmet medical needs.
Although Bellevue did not provide much information on the potential transaction, it expects to finalize the definitive agreement within the coming weeks and will announce additional details at that time. With a November 14 completion deadline, the parties intend to complete the business combination in the fourth quarter of 2023.
Upon completion of the business combination, the surviving company will be renamed OSR Biosciences, Inc.
OSR Holdings currently wholly owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.
Additionally, OSR Holdings signed a separate LOI on July 7 to acquire Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology.
Bellevue Life Sciences priced its $60 million IPO earlier this year in February and initially set out to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. The SPAC is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
Armada Acquisition Corp. II has filed for a $200 million SPAC to combine with a fintech, SaaS or AI company with nearly the same team top-to-bottom that just completed its first SPAC combination in that space. The filing is Cohen & Company’s seventh of the year as left-lead underwriter and Northland Capital Markets is stepping in...
HCM II (NASDAQ:HOND) has entered into a definitive agreement to combine with nuclear reactor developer Terrestrial Energy at a pro forma equity value of $1.3 billion. Charlotte, North Carolina-based Terrestrial is developing unique molten salt nuclear reactors designed to generate enhanced heat outputs for industrial client processes. The combined company is expected to trade on...
At the SPAC of Dawn Rain or shine, legal challenges for SPACs do not appear to be going anywhere. Cornerstone Research found this week that the number of securities class action lawsuit settlements increased +6% in 2024 and suits targeted at SPACs or de-SPACs represented 19% of this total. On the plus side, the median...
At the SPAC of Dawn A new conservative stock with meme potential is further taking shape as the market finds its footing this week. Firearms marketplace GrabAGun nominated its Board that will take their seats after the company completes its combination with Colombier II (NYSE:CLBR) anticipated later this summer. This Board includes Donald Trump Jr.,...
Berto Acquisition Corp. (NASDAQ:TACOU) has filed for a $250 million SPAC to continue a long-running series by a repeat sponsor under a new name and this will be its first go-around with underwriter Cohen & Company. This new SPAC is not overfunded and will have 24 months initially to complete a transaction with 1/2 warrants...